Jaguar Health
201 Mission Street Suite 2375
San Francisco
CA
94105
United States
Tel: 415-999-7092
Website: https://jaguar.health/
236 articles about Jaguar Health
-
Jaguar Health Announces Commitment to Move Forward with Exclusive Relationship with the Planned Dragon SPAC, which is Pursuing Listing on AIM Italia and Plans to Target Napo EU
2/19/2021
Napo EU continues to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe
-
Jaguar Health Signs Memorandum of Understanding with the Lead Sponsor of the Planned Dragon SPAC Pursuing Listing on AIM Italia, Providing the Dragon SPAC with Exclusivity for a Proposed Business Combination with Napo EU
2/18/2021
Napo EU to explore conditional marketing authorization for proposed inflammatory diarrhea indication for crofelemer, initially in ‘long-hauler' covid-19 recovery patients in Europe
-
Noted Natural Products Industry Veteran Dr. Nigel Gericke Joins Scientific Strategy Team for Jaguar Health’s Recently Launched Mental Health Entheogen Therapeutics Initiative
2/9/2021
Jaguar Health announced today that noted natural products industry veteran Dr. Nigel Gericke has joined the scientific strategy team (SST) for the company's recently launched mental health Entheogen Therapeutics Initiative
-
Jaguar Health's Chief of Sustainable Supply, Dr. Steven King, an Ethnobotanist, to Discuss Crofelemer Development on February 4th at 2 PM Eastern
2/3/2021
Webinar Title: The Development of Crofelemer: Connecting Ethnobotany, Conservation, Biocultural Diversity, Indigenous Knowledge and Global Public Health
-
REMINDER: Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time
1/26/2021
Webcast registration link appears below Andreea Porcelli, CEO of Swiss Growth Forum, will be a co-presenter on the webcast in her separate capacity as a sponsor of the proposed SPAC Andreea Porcelli and Jaguar CEO Lisa Conte interviewed again on Innovators with Jane King
-
Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1/22/2021
Jaguar Health, Inc. (NASDAQ:JAGX) announced today that effective December 9, 2020, the Company granted nonstatutory stock options for the purchase of up to 1,500 shares of the Companys common stock to one new employee, and nonstatutory stock options for the purchase of up to 35,000 shares of the Companys common stock
-
Jaguar Health Regains Compliance with Nasdaq’s Bid Price Requirement
1/22/2021
Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today announced that on January 21, 2021 the Company received formal notice that Jaguar has regained compliance with the bid price requirement, as required by the decision of the Nasdaq Hearings Panel (the "Panel") dated October 28, 2020 (the "Decision").
-
Jaguar Health and Sponsor of Proposed Post Pandemic Recovery Equity SPAC to Host Webcast Wednesday, January 27th at 8:30 AM Eastern Time
1/21/2021
Jaguar Health, Inc. announced today that the Company and a sponsor of the proposed Post Pandemic Recovery Equity special purpose acquisition company ("the SPAC") are hosting a webcast on Wednesday, January 27, 2021 at 8:30 AM Eastern Time
-
Jaguar Health Announces Closing of $6.0 Million Issuance and Sale of Designation-backed Note Related to Possible Tropical Disease Priority Review Voucher
1/20/2021
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients and severe acute watery diarrhea
-
Jaguar Health Provides Replay Link & High-level Overview of January 14th Investor Webcast
1/15/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today provided the replay link for the Companys January 14, 2021 investor webcast and a recap of the key points from the presentation.
-
Jaguar Health Enters Non-dilutive Binding Term Sheet for $6.0 Million Sale of Partial Rights to Possible Tropical Disease Priority Review Voucher
1/13/2021
This additional non-dilutive financing will support development program for lechlemer for the indication of the symptomatic relief of diarrhea and dehydration in cholera patients REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time. Webcast registration and participation link appears below
-
Jaguar Health Announces $15 Million Registered Direct Offering Priced Above-the-Market Under Nasdaq Rules
1/13/2021
Jaguar Health, Inc. (NASDAQ:JAGX) today announced it has entered into a securities purchase agreement with two institutional investors including a high-net-worth family office for the purchase and sale of 4,437,870 shares of common stock at a purchase price of $3.38 per share for gross proceeds of approximately $15.0 million in a registered direct offering priced above-the-market under Nasdaq rules
-
Jaguar Health to Present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference the Week of January 11th and at 4:30 pm Eastern on Tuesday, January 19th at the NobleCon17 Virtual Conference
1/12/2021
REMINDER: Jaguar-hosted investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
-
Jaguar Health Exploring Possibility of Conditional Marketing Authorization for Proposed Inflammatory Diarrhea Indication for Crofelemer, Initially in ‘Long-Hauler’ COVID-19 Recovery Patients in Europe
1/11/2021
New COVID-19 strain estimated to have tripled number of infections in England during November 2020 lockdown Investor webcast scheduled for Thursday, January 14 at 11:30 A.M. Eastern Time.
-
Jaguar Health Subsidiary Receiving Preclinical Services from the NIAID for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
1/6/2021
Jaguar Health, Inc. announced that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera.
-
Jaguar Health Signs Second Agreement for $6 Million Non-dilutive Financing Transaction Involving the Sale of Royalty Rights Related to Future Mytesi (Crofelemer) and Lechlemer Revenue Stream
12/23/2020
No royalty payments due for 18-24 months Proceeds will be allocated to support regulatory activities associated with the Companys development pipeline, including funding the recently initiated pivotal clinical trial for crofelemer for cancer therapy-related diarrhea (CTD), for which patient enrollment is progressing
-
Jaguar Health Reports Voting Results from Special Meeting of Stockholders & Announces December 23rd Investor Webinar
12/22/2020
All proposals approved Company not implementing a reverse split at this time Swiss Growth Forum hosting investor webinar Wednesday, December 23rd at 10:30 AM Eastern
-
Jaguar Health to Host Investor Call Thursday, December 17, 2020
12/15/2020
Jaguar Health Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") issued a reminder today that Company management is hosting an investor call on Thursday, December 17th at 8:30 a.m. Eastern Standard Time
-
Jaguar Health Announces Adjournment of Its Special Meeting of Stockholders Until Tuesday, December 22, 2020
12/10/2020
Jaguar to Host Investor Call Thursday, December 17th at 8:30 a.m. Eastern to Allow Management to Review Developments that Have Taken Place Since the Definitive Proxy Statement was Filed As previously announced, Nasdaqs Listing and Hearing Review Council Stayed the Panel Determination Requiring Jaguars Compliance with the Bid Price Requirement by December 23, 2020
-
Nasdaq's Listing and Hearing Review Council Stays Panel Determination Requiring Jaguar Health's Compliance with the Bid Price Requirement by December 23, 2020
12/7/2020
The Nasdaq Listing Council, on its own motion, will consider if the Company should have been granted a longer period within which to evidence compliance with the $1.00 per share minimum bid price requirement